Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results

Core Viewpoint - Belite Bio, Inc is set to host a webcast on March 2, 2026, to discuss its financial results and provide a business update for Q4 and the full year ended December 31, 2025 [1]. Company Overview - Belite Bio is a clinical-stage drug development company focused on creating novel therapeutics for degenerative retinal diseases with significant unmet medical needs, including Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD) [3]. - The company's lead candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of bisretinoid toxins in the eye [3]. - Belite Bio has completed a Phase 3 trial (DRAGON) in adolescent STGD1 subjects and is currently conducting a Phase 2/3 trial (DRAGON II) in the same demographic, as well as a Phase 3 trial (PHOENIX) in subjects with GA [3]. Webcast Information - The webcast will take place on March 2, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) [2]. - A replay of the webcast will be available for approximately 90 days after the event [2].